«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2023年06期

页码:

809-813

栏目:

论著

出版日期:

2023-12-20

文章信息/Info

Title:

Clinical features and management of non-transplant patients with invasive pulmonary aspergillosis: analysis of 32 cases

作者:

陈 勇¹; 任建伟¹; 朱光发¹; 刘玉磊²; 吴绍芹³

100029 北京, 首都医科大学附属北京安贞医院呼吸与危重症医学科¹、临床实验室²、放射科³

Author(s):

Chen Yong¹;  Ren Jianwei¹;  Zhu Guangfa¹;  Liu Yulei²;  Wu Shaoqin³.

¹Department of Respiration and Critical Care Medicine; ²Department of Clinical Laboratory; ³Department of Radiology, Capital Medical University Affiliated Beijing Anzhen Hospital, Beijing 100029, China

关键词:

侵袭性肺曲霉病;  诊断/治疗;  临床特征

Keywords:

Invasive pulmonary aspergillosis;  Diagnosis/treatment;  Clinical features

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2023.06.013

摘要:

目的 分析非移植患者侵袭性肺曲霉病(invasive pulmonary aspergillosis, IPA)的临床特征与治疗。 方法 回顾性分析2015年1月至2021年8月我院住院治疗的32例侵袭性肺曲霉病的临床表现、微生物学检查、胸部影像学、诊治经过及转归等。 结果 经过临床检查,3例确诊,27例临床诊断,2例拟诊。继发性侵袭性肺曲霉病31例,原发性侵袭性肺曲霉病1例,其中基础肺部疾病20例(62.5%)和应用糖皮质激素10例(31.3%)是最常见的基础疾病和危险因素。主要临床表现为咳嗽、咳痰30例(93.8%)、呼吸困难25例(78.1%)、发热16例(50.0%)和肺部啰音23例(71.8%)。胸部CT平扫以斑片影31例(96.8%)、实变影21例(65.6%)、结节影20例(62.5%)及空洞影15例(46.8%)最常见。血清G试验28例,阳性19例(67.9%)和GM试验16例,其中阳性11例(68.7%),16例(50.0%)痰培养阳性中,以黄曲霉、烟曲霉常见。患者接受伏立康唑、两性霉素B及其脂质复合体、卡泊芬净单药或联合治疗,总疗程约8～12周,住院时间平均为20.5 d,共治愈8例,好转14例,无效4例,死亡6例。结论 非移植患者侵袭性肺曲霉病病情凶险,临床表现缺乏特异性,临床怀疑时,尽早完善微生物学等检查,及时进行分层诊断和治疗,以改善IPA患者的预后。

Abstract:

Objective To describe the characteristics and management of non-transplant patients with invasive pulmonary aspergillosis(IPA). Methods The clinical manifestation, microbiological examination, chest imaging, diagnosis, treatment and outcomes of 32 non-transplant patients with IPA from Capital Medical University Affiliated Beijing Anzhen Hospital from January 2015 to August 2021 were retrospectively collected and described. Results 3 cases fulfilled the criteria of proven IPA, 27 of probable an 2 of possible IPA, and among the 32 patients. One case was primary IPA, and 31 cases were secondary IPA, among which chronic pulmonary diseases 20 cases(62.5%)and uses of glucocorticoid 10 cases(31.3%)were the most common basic diseases and risk factors. The main clinical manifestations included cough 30 cases(93.8%), sputum production 30 cases(93.8%), dyspnea 25 cases(78.1%), fever 16 cases(50.0%)and lung rales 23 cases(71.8%). The chest imaging mainly included patchy infiltrates 31 cases(96.8%), consolidation 21 cases(65.6%), nodules 20 cases(62.5%)and cavities 15 cases(46.8%). 28 cases with glucan(G)test, 19 cases positive plasme(67.9%). 16 cases with plasma galactomannan(GM)test, positive 11 cases(68.7%). 16 cases positive sputum cultures(50%), which mainly included Aspergillosis flavus and Aspergillosis fumigatus. All patients received Voriconazole, Amphotericin B, Amphotericin B Liposome and Caspofungin Acetate therapy alone or in combination and the total course of treatment was about 8-12 weeks. The mean length of stay was 20.5 days(2～123 days). 8 cases were cured, 14 cases improved, 4 cases failed and 6 cases died. Conclusions IPA in non-transplant patients is usually insidious at onset without specific manifestations. When clinically suspected, microbiological examination should be done as soon as possible, and graded treatment should be given according to hierarchical diagnosis to improve the prognosis.

参考文献/References:

1 Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America[J]. Clin Infect Dis, 2016, 63(4): e1-e60.
2 Brown GD, Denning DW, Gow NA, et al. Hidden killers: Human fungal infections[J]. Sci Transl Med, 2012, 4(165): 1-9.
3 陈先华, 郝 飞. 侵袭性肺曲霉病的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2015, 9(2): 201-203.
4 Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis, 2020, 71(6): 1367-1376.
5 中华医学会呼吸病学分会感染学组. 肺真菌病诊断和治疗专家共识[J]. 中华结核和呼吸杂志, 2007, 30(11): 821-834.
6 胡小燕, 周 华, 符一骐, 等. 免疫缺陷患者侵袭性肺曲霉病的临床分析[J]. 中国感染与化疗杂志, 2021, 21(4): 394-398.
7 任成山, 郭乔楠. 进一步提高对下呼吸道念珠菌感染的认识[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(5): 471-478.
8 任之栋, 张 巧, 马千里. 慢性阻塞性肺疾病合并肺曲霉病的诊断研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(2): 272-275.
9 Taccone FS, Van den Abeele AM, Bulpa P, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes[J]. Crit Care, 2015, 19(1): 7.
10 Roilides E, Blake C, Holmes A, et al. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae[J]. J Med Vet Mycol, 1996, 34(1): 63-69.
11 Vaideeswar P, Prasad S, Deshpande JR, et al. Invasive pulmonary aspergillosis: A study of 39 cases at autopsy[J]. J Postgrad Med, 2004, 50(1): 21-26.
12 Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus[J]. Clin Infect Dis, 2002, 34(1): 7-14.
13 Bassetti M, Peghin M, Vena A. Challenges and solution of invasive aspergillosis in non-neutropenic patients: A review[J]. Infect Dis Ther, 2018, 7(1): 17-27.
14 Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological,clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey[J]. Clin Infect Dis, 2006, 43(5): 577-584.
15 Pazos C, Pontón J, Del Palacio A. Contribution of(1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan[J]. J Clin Microbiol, 2005, 43(1): 299-305.
16 Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients[J]. Am J Respir Crit Care Med, 2008, 177(1): 27-34.
17 Patterson KC, Strek ME. Diagnosis and treatment of pulmonary aspergillosis syndromes[J]. Chest, 2014, 146(5): 1358-1368.
18 Walicka-Serzysko K, Sands D. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis-preliminary report[J]. Dev Period Med, 2015, 19(1): 66-79.
19 Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis[J]. Thorax, 2015, 70(3): 270-277.
20 Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis[J]. Clin Infect Dis, 2004, 39(6): 797-802.
21 Chabi ML, Goracci A, Roche N, et al. Pulmonary aspergillosis[J]. Diagn Interv Imaging, 2015, 96(5): 435-442.
22 Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis[J]. Int J Infect Dis, 2014, 28: 80-94.
23 Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study[J]. Transplantation, 2006, 81(3): 320-326.
24 Thomas A, Korb V, Guillemain R, et al.Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis[J]. J Clin Pharm Ther, 2010, 35(1): 49-53.
25 MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis[J]. Antimicrob Agents Chemother, 2005, 49(9): 3697-3701.
26 Pavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis[J]. J Clin Microbiol, 2005, 43(9): 4902-4904.
27 Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients[J]. Transplant Proc, 2007, 39(6): 1838-1840.

备注/Memo

备注/Memo:

通信作者: 朱光发, Email:gfzhu63@hotmail.com

常用功能

更新日期/Last Update: 2023-12-20